Guidance Reaffirmation and Investor Day Plans Put Focus on Execution
Scotts Miracle-Gro (SMG) reaffirmed its full fiscal 2026 guidance, citing positive year-to-date branded consumer POS dollars and locked-in commodity costs. The company also outlined an upcoming Investor Day centered on mid to long term priorities.
See our latest analysis for Scotts Miracle-Gro.
At a share price of US$56.97, Scotts Miracle-Gro has seen its 90-day share price return fall 13.9%, while the 1-year total shareholder return is modestly positive at 1.6%. This suggests longer term performance has been steadier than recent trading momentum.
If you want to see what else is catching investors’ attention around consumer and infrastructure themes, this could be a good moment to broaden your search with 20 top founder-led companies
With the stock trading at US$56.97 and flagged as at a discount to some intrinsic and analyst estimates, investors now face a key question: is there genuine upside left, or is the market already pricing in future growth?
Most Popular Narrative: 31% Overvalued
Compared with the last close at $56.97, the most followed narrative sets fair value at $43.49, putting a clear spotlight on how that gap is justified.
SMG’s current valuation reflects lingering skepticism: concerns over cannabis demand, consumer spending softness, and execution risk. But it may also underappreciate the company’s positioning within professional cultivation.
Scotts Miracle-Gro is evolving alongside that reality, moving from a consumer brand to a cultivation partner. The transition will not happen overnight, and volatility will persist. Read the complete narrative.
Want to understand why a company with modest forecast revenue growth still gets a premium narrative? The key levers are margin repair, earnings quality, and what multiple those profits could justify.
Result: Fair Value of $43.49 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story could shift quickly if cannabis cultivation demand weakens further or if execution on hydroponics and professional cultivation fails to translate into sustained profitability.
Find out about the key risks to this Scotts Miracle-Gro narrative.
Another Take: Multiples Point to a Different Story
While the most popular narrative tags Scotts Miracle-Gro as 31% overvalued at a fair value of $43.49, current metrics tell a different story. The stock trades on a P/E of 16.1x, compared with 28x for the US Chemicals industry and 53.9x for peers, and below an estimated fair ratio of 18.4x. That gap suggests the market is pricing in more risk than these benchmarks imply. The question for investors is which signal to prioritize.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed signals around valuation and execution, do you want to rely on the crowd or your own homework? Take a closer look at the full picture by weighing the 6 key rewards and 1 important warning sign.
Looking for more investment ideas?
If you stop here, you only see one stock’s story. Use this moment to widen your watchlist and pressure test your thinking across different types of opportunities.
- Spot potential mispricing early by scanning 47 high quality undervalued stocks that combine quality fundamentals with market skepticism.
- Build a sturdier core to your portfolio with the solid balance sheet and fundamentals stocks screener (47 results) and stress test how much risk you really want to carry.
- Get ahead of the crowd by studying the screener containing 22 high quality undiscovered gems before they sit on everyone else’s radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com